Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Monodox

×

Overview

What is Monodox?

Doxycycline is a broad-spectrum antibacterial synthetically derived from oxytetracycline. MONODOX 100 mg, 75 mg, and 50 mg capsules contain doxycycline monohydrate equivalent to 100 mg, 75 mg, or 50 mg of doxycycline for oral administration. The chemical designation of the light-yellow crystalline powder is alpha-6-deoxy-5-oxytetracycline.

Structural formula:

CHNO • HO      M.W. = 462.45

Doxycycline has a high degree of lipid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. Doxycycline will not degrade into an epianhydro form.

Inert ingredients: colloidal silicon dioxide; magnesium stearate; microcrystalline cellulose; sodium starch glycolate; and a hard gelatin capsule which contains black iron oxide, red iron oxide, titanium dioxide, and yellow iron oxide for the 100 mg and 75 mg strengths, titanium dioxide and yellow iron oxide for the 50 mg strength. The capsules are printed with edible ink containing black iron oxide, red iron oxide, and yellow iron oxide for the 50 mg and 100 mg strengths and black iron oxide, FD&C Blue No. 2, FD&C Red No. 40, FD&C Blue No. 1, and D&C Yellow No. 10 for the 75 mg strength.



What does Monodox look like?



What are the available doses of Monodox?

Sorry No records found.

What should I talk to my health care provider before I take Monodox?

Sorry No records found

How should I use Monodox?

INDICATIONS AND USAGE

To reduce the development of drug-resistant bacteria and maintain effectiveness of MONODOX and other antibacterial drugs, MONODOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Doxycycline is indicated for the treatment of the following infections:     Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae.     Respiratory tract infections caused by     Lymphogranuloma venereum caused by     Psittacosis (ornithosis) caused by     Trachoma caused by although the infectious agent is not always eliminated as judged by immunofluorescence.     Inclusion conjunctivitis caused by     Uncomplicated urethral, endocervical or rectal infections in adults caused by     Nongonococcal urethritis caused by     Relapsing fever due to

Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms:     Chancroid caused by     Plague due to     Tularemia due to     Cholera caused by     Campylobacter fetus infections caused by     Brucellosis due to (in conjunction with streptomycin).     Bartonellosis due to     Granuloma inguinale caused by

Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended.

Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug:                         Respiratory tract infections caused by     Respiratory tract and urinary tract infections caused by

Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:     Upper respiratory infections caused by     Anthrax due to including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized

When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections:     Uncomplicated gonorrhea caused by     Syphilis caused by     Yaws caused by subspecies     Listeriosis due to     Vincent’s infection caused by     Actinomycosis caused by     Infections caused by

In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides.

In severe acne, doxycycline may be useful adjunctive therapy.

THE USUAL DOSAGE AND FREQUENCY OF ADMINISTRATION OF DOXYCYCLINE DIFFERS FROM THAT OF THE OTHER TETRACYCLINES. EXCEEDING THE RECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE OF SIDE EFFECTS.

Adults:

Pediatric Patients:

For all pediatric patients weighing less than 45 kg with severe or life-threatening infections (e.g. anthrax, Rocky Mountain spotted fever), the recommended dosage is 2.2 mg/kg of body weight administered every 12 hours. Children weighing 45 kg or more should receive the adult dose (See and ).

For pediatric patients with less severe disease (greater than 8 years of age and weighing less than 45 kg), the recommended dosage schedule is 4.4 mg per kg of body weight divided into two doses on the first day of treatment, followed by a maintenance dose of 2.2 mg per kg of body weight (given as a single daily dose or divided into twice daily doses). For pediatric patients weighing over 45 kg, the usual adult dose should be used.

The therapeutic antibacterial serum activity will usually persist for 24 hours following recommended dosage.

When used in streptococcal infections, therapy should be continued for 10 days.

Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration. (See )

If gastric irritation occurs, it is recommended that doxycycline be given with food or milk. The absorption of doxycycline is not markedly influenced by simultaneous ingestion of food or milk.

Studies to date have indicated that administration of doxycycline at the usual recommended doses does not lead to excessive accumulation of doxycycline in patients with renal impairment.

Uncomplicated gonococcal infections in adults (except anorectal infections in men):

Acute epididymo-orchitis caused by

Primary and secondary syphilis:

Uncomplicated urethral, endocervical, or rectal infection in adults caused by

Nongonococcal urethritis caused by

and

Acute epididymo-orchitis caused by

Inhalational anthrax (post-exposure):


What interacts with Monodox?

Sorry No Records found


What are the warnings of Monodox?

Sorry No Records found


What are the precautions of Monodox?

Sorry No Records found


What are the side effects of Monodox?

Sorry No records found


What should I look out for while using Monodox?

This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.

The use of drugs of the tetracycline class, including doxycycline, during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). This adverse reaction is more common during long-term use of the drugs, but it has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. Use of doxycycline in pediatric patients 8 years of age or less only when the potential benefits are expected to outweigh the risks in severe or life-threatening conditions (e.g. anthrax, Rocky Mountain spotted fever), particularly when there are no alternative therapies.

Clostridium difficile

C. difficile

C. difficile

C. difficile

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of , and surgical evaluation should be instituted as clinically indicated.

Intracranial hypertension (IH, pseudotumor cerebri) has been associated with the use of tetracyclines including MONODOX. Clinical manifestations of IH include headache, blurred vision, diplopia, and vision loss; papilledema can be found on fundoscopy. Women of childbearing age who are overweight or have a history of IH are at greater risk for developing tetracycline associated IH. Concomitant use of isotretinoin and MONODOX should be avoided because isotretinoin is also known to cause pseudotumor cerebri.

Although IH typically resolves after discontinuation of treatment, the possibility for permanent visual loss exists. If visual disturbance occurs during treatment, prompt ophthalmologic evaluation is warranted. Since intracranial pressure can remain elevated for weeks after drug cessation patients should be monitored until they stabilize.

All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in the fibula growth rate has been observed in prematures given oral tetracycline in doses of 25 mg/kg every six hours. This reaction was shown to be reversible when the drug was discontinued.

Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryo toxicity has been noted in animals treated early in pregnancy. If any tetracycline is used during pregnancy or if the patient becomes pregnant while taking these drugs, the patient should be apprised of the potential hazard to the fetus.

The antianabolic action of the tetracyclines may cause an increase in BUN. Studies to date indicate that this does not occur with the use of doxycycline in patients with impaired renal function.

Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.


What might happen if I take too much Monodox?

In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Dialysis does not alter serum half-life, and it would not be of benefit in treating cases of overdosage.


How should I store and handle Monodox?

Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F) . Avoid high humidity. MONODOX 50 mg Capsules have a white opaque body with a yellow opaque cap. The capsule bears the inscription “MONODOX 50” in brown and “M 260” in brown. Each capsule contains doxycycline monohydrate equivalent to 50 mg doxycycline.MONODOX 50 mg is available in: MONODOX 75 mg Capsules have a white opaque body with a brown opaque cap. The capsule bears the inscription "MONODOX 75" in black and "M 075" in black. Each capsule contains doxycycline monohydrate equivalent to 75 mg doxycycline.MONODOX 75 mg is available in:       Bottles of 100 capsules ......................................................NDC 16110-075-01MONODOX 100 mg Capsules have a yellow opaque body with a brown opaque cap. The capsule bears the inscription “MONODOX 100” in white and “M 259” in brown. Each capsule contains doxycycline monohydrate equivalent to 100 mg of doxycycline.MONODOX 100 mg is available in:       Bottles of 50 capsules ........................................................NDC 16110-259-04       Bottles of 250 capsules ......................................................NDC 16110-259-07 STORE AT 20° - 25°C (68° - 77°F) WITH EXCURSIONS PERMITTED TO 15° C TO 30°C (59° TO 86°F). [SEE USP CONTROLLED ROOM TEMPERATURE.]DISPENSE IN A TIGHT LIGHT-RESISTANT CONTAINER AS DEFINED IN THE USP/NF.MONODOX 50 mg Capsules have a white opaque body with a yellow opaque cap. The capsule bears the inscription “MONODOX 50” in brown and “M 260” in brown. Each capsule contains doxycycline monohydrate equivalent to 50 mg doxycycline.MONODOX 50 mg is available in: MONODOX 75 mg Capsules have a white opaque body with a brown opaque cap. The capsule bears the inscription "MONODOX 75" in black and "M 075" in black. Each capsule contains doxycycline monohydrate equivalent to 75 mg doxycycline.MONODOX 75 mg is available in:       Bottles of 100 capsules ......................................................NDC 16110-075-01MONODOX 100 mg Capsules have a yellow opaque body with a brown opaque cap. The capsule bears the inscription “MONODOX 100” in white and “M 259” in brown. Each capsule contains doxycycline monohydrate equivalent to 100 mg of doxycycline.MONODOX 100 mg is available in:       Bottles of 50 capsules ........................................................NDC 16110-259-04       Bottles of 250 capsules ......................................................NDC 16110-259-07 STORE AT 20° - 25°C (68° - 77°F) WITH EXCURSIONS PERMITTED TO 15° C TO 30°C (59° TO 86°F). [SEE USP CONTROLLED ROOM TEMPERATURE.]DISPENSE IN A TIGHT LIGHT-RESISTANT CONTAINER AS DEFINED IN THE USP/NF.MONODOX 50 mg Capsules have a white opaque body with a yellow opaque cap. The capsule bears the inscription “MONODOX 50” in brown and “M 260” in brown. Each capsule contains doxycycline monohydrate equivalent to 50 mg doxycycline.MONODOX 50 mg is available in: MONODOX 75 mg Capsules have a white opaque body with a brown opaque cap. The capsule bears the inscription "MONODOX 75" in black and "M 075" in black. Each capsule contains doxycycline monohydrate equivalent to 75 mg doxycycline.MONODOX 75 mg is available in:       Bottles of 100 capsules ......................................................NDC 16110-075-01MONODOX 100 mg Capsules have a yellow opaque body with a brown opaque cap. The capsule bears the inscription “MONODOX 100” in white and “M 259” in brown. Each capsule contains doxycycline monohydrate equivalent to 100 mg of doxycycline.MONODOX 100 mg is available in:       Bottles of 50 capsules ........................................................NDC 16110-259-04       Bottles of 250 capsules ......................................................NDC 16110-259-07 STORE AT 20° - 25°C (68° - 77°F) WITH EXCURSIONS PERMITTED TO 15° C TO 30°C (59° TO 86°F). [SEE USP CONTROLLED ROOM TEMPERATURE.]DISPENSE IN A TIGHT LIGHT-RESISTANT CONTAINER AS DEFINED IN THE USP/NF.MONODOX 50 mg Capsules have a white opaque body with a yellow opaque cap. The capsule bears the inscription “MONODOX 50” in brown and “M 260” in brown. Each capsule contains doxycycline monohydrate equivalent to 50 mg doxycycline.MONODOX 50 mg is available in: MONODOX 75 mg Capsules have a white opaque body with a brown opaque cap. The capsule bears the inscription "MONODOX 75" in black and "M 075" in black. Each capsule contains doxycycline monohydrate equivalent to 75 mg doxycycline.MONODOX 75 mg is available in:       Bottles of 100 capsules ......................................................NDC 16110-075-01MONODOX 100 mg Capsules have a yellow opaque body with a brown opaque cap. The capsule bears the inscription “MONODOX 100” in white and “M 259” in brown. Each capsule contains doxycycline monohydrate equivalent to 100 mg of doxycycline.MONODOX 100 mg is available in:       Bottles of 50 capsules ........................................................NDC 16110-259-04       Bottles of 250 capsules ......................................................NDC 16110-259-07 STORE AT 20° - 25°C (68° - 77°F) WITH EXCURSIONS PERMITTED TO 15° C TO 30°C (59° TO 86°F). [SEE USP CONTROLLED ROOM TEMPERATURE.]DISPENSE IN A TIGHT LIGHT-RESISTANT CONTAINER AS DEFINED IN THE USP/NF.MONODOX 50 mg Capsules have a white opaque body with a yellow opaque cap. The capsule bears the inscription “MONODOX 50” in brown and “M 260” in brown. Each capsule contains doxycycline monohydrate equivalent to 50 mg doxycycline.MONODOX 50 mg is available in: MONODOX 75 mg Capsules have a white opaque body with a brown opaque cap. The capsule bears the inscription "MONODOX 75" in black and "M 075" in black. Each capsule contains doxycycline monohydrate equivalent to 75 mg doxycycline.MONODOX 75 mg is available in:       Bottles of 100 capsules ......................................................NDC 16110-075-01MONODOX 100 mg Capsules have a yellow opaque body with a brown opaque cap. The capsule bears the inscription “MONODOX 100” in white and “M 259” in brown. Each capsule contains doxycycline monohydrate equivalent to 100 mg of doxycycline.MONODOX 100 mg is available in:       Bottles of 50 capsules ........................................................NDC 16110-259-04       Bottles of 250 capsules ......................................................NDC 16110-259-07 STORE AT 20° - 25°C (68° - 77°F) WITH EXCURSIONS PERMITTED TO 15° C TO 30°C (59° TO 86°F). [SEE USP CONTROLLED ROOM TEMPERATURE.]DISPENSE IN A TIGHT LIGHT-RESISTANT CONTAINER AS DEFINED IN THE USP/NF.MONODOX 50 mg Capsules have a white opaque body with a yellow opaque cap. The capsule bears the inscription “MONODOX 50” in brown and “M 260” in brown. Each capsule contains doxycycline monohydrate equivalent to 50 mg doxycycline.MONODOX 50 mg is available in: MONODOX 75 mg Capsules have a white opaque body with a brown opaque cap. The capsule bears the inscription "MONODOX 75" in black and "M 075" in black. Each capsule contains doxycycline monohydrate equivalent to 75 mg doxycycline.MONODOX 75 mg is available in:       Bottles of 100 capsules ......................................................NDC 16110-075-01MONODOX 100 mg Capsules have a yellow opaque body with a brown opaque cap. The capsule bears the inscription “MONODOX 100” in white and “M 259” in brown. Each capsule contains doxycycline monohydrate equivalent to 100 mg of doxycycline.MONODOX 100 mg is available in:       Bottles of 50 capsules ........................................................NDC 16110-259-04       Bottles of 250 capsules ......................................................NDC 16110-259-07 STORE AT 20° - 25°C (68° - 77°F) WITH EXCURSIONS PERMITTED TO 15° C TO 30°C (59° TO 86°F). [SEE USP CONTROLLED ROOM TEMPERATURE.]DISPENSE IN A TIGHT LIGHT-RESISTANT CONTAINER AS DEFINED IN THE USP/NF.MONODOX 50 mg Capsules have a white opaque body with a yellow opaque cap. The capsule bears the inscription “MONODOX 50” in brown and “M 260” in brown. Each capsule contains doxycycline monohydrate equivalent to 50 mg doxycycline.MONODOX 50 mg is available in: MONODOX 75 mg Capsules have a white opaque body with a brown opaque cap. The capsule bears the inscription "MONODOX 75" in black and "M 075" in black. Each capsule contains doxycycline monohydrate equivalent to 75 mg doxycycline.MONODOX 75 mg is available in:       Bottles of 100 capsules ......................................................NDC 16110-075-01MONODOX 100 mg Capsules have a yellow opaque body with a brown opaque cap. The capsule bears the inscription “MONODOX 100” in white and “M 259” in brown. Each capsule contains doxycycline monohydrate equivalent to 100 mg of doxycycline.MONODOX 100 mg is available in:       Bottles of 50 capsules ........................................................NDC 16110-259-04       Bottles of 250 capsules ......................................................NDC 16110-259-07 STORE AT 20° - 25°C (68° - 77°F) WITH EXCURSIONS PERMITTED TO 15° C TO 30°C (59° TO 86°F). [SEE USP CONTROLLED ROOM TEMPERATURE.]DISPENSE IN A TIGHT LIGHT-RESISTANT CONTAINER AS DEFINED IN THE USP/NF.MONODOX 50 mg Capsules have a white opaque body with a yellow opaque cap. The capsule bears the inscription “MONODOX 50” in brown and “M 260” in brown. Each capsule contains doxycycline monohydrate equivalent to 50 mg doxycycline.MONODOX 50 mg is available in: MONODOX 75 mg Capsules have a white opaque body with a brown opaque cap. The capsule bears the inscription "MONODOX 75" in black and "M 075" in black. Each capsule contains doxycycline monohydrate equivalent to 75 mg doxycycline.MONODOX 75 mg is available in:       Bottles of 100 capsules ......................................................NDC 16110-075-01MONODOX 100 mg Capsules have a yellow opaque body with a brown opaque cap. The capsule bears the inscription “MONODOX 100” in white and “M 259” in brown. Each capsule contains doxycycline monohydrate equivalent to 100 mg of doxycycline.MONODOX 100 mg is available in:       Bottles of 50 capsules ........................................................NDC 16110-259-04       Bottles of 250 capsules ......................................................NDC 16110-259-07 STORE AT 20° - 25°C (68° - 77°F) WITH EXCURSIONS PERMITTED TO 15° C TO 30°C (59° TO 86°F). [SEE USP CONTROLLED ROOM TEMPERATURE.]DISPENSE IN A TIGHT LIGHT-RESISTANT CONTAINER AS DEFINED IN THE USP/NF.


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Tetracyclines are readily absorbed and are bound to plasma proteins in varying degrees. They are concentrated by the liver in the bile and excreted in the urine and feces at high concentrations in a biologically active form. Doxycycline is virtually completely absorbed after oral administration.

Following a 200 mg dose of doxycycline monohydrate, 24 normal adult volunteers averaged the following serum concentration values:

Average Observed Values

Excretion of doxycycline by the kidney is about 40%/72 hours in individuals with normal function (creatinine clearance about 75 mL/min). This percentage excretion may fall as low as 1-5%/72 hours in individuals with severe renal insufficiency (creatinine clearance below 10 mL/min). Studies have shown no significant difference in serum half-life of doxycycline (range 18-22 hours) in individuals with normal and severely impaired renal function.

Hemodialysis does not alter serum half-life.

Microbiology:

Mechanism of Action

ResistanceCross resistance with other tetracyclines is common.

Antimicrobial Activity

in vitro

(see

GramNegative Bacteria

Acinetobacter

Bartonella bacilliformis

Brucella

Campylobacter fetus

Enterobacter aerogenes

Escherichia coli

Francisella tularensis

Haemophilus ducreyi

Haemophilus influenzae

Klebsiella granulomatis

Klebsiella

Neisseria gonorrhoeae

Shigella

Vibrio cholerae

Yersinia pestis

GramPositive Bacteria

Bacillus anthracis

Listeria monocytogenes

Streptococcus pneumoniae

Anaerobic Bacteria

Clostridium species

Fusobacterium fusiforme

Propionibacterium acnes

Other Bacteria

Nocardiae and

Actinomyces

Borrelia recurrentis

Chlamydophila psittaci

Chlamydia trachomatis

Mycoplasma pneumoniae

Rickettsiae

Treponema pallidum

Treponema pallidum

pertenue

Ureaplasma urealyticum

Parasites

Balantidium coli

Entamoeba

Susceptibility Testing Methods

in vitro

Dilution Techniques

Diffusion Techniques

Anaerobic Techniques

A report of (S) indicates that the antimicrobial is likely to inhibit growth of the microorganism if the antimicrobial drug reaches the concentration usually achievable at the site of infection. A report of (I) indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug product is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of (R) indicates that the antimicrobial drug is not likely to inhibit growth of the microorganism if the antimicrobial drug reaches the concentrations usually achievable at the infection site; other therapy should be selected.

Quality Control

Non-Clinical Toxicology
This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.

The use of drugs of the tetracycline class, including doxycycline, during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). This adverse reaction is more common during long-term use of the drugs, but it has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. Use of doxycycline in pediatric patients 8 years of age or less only when the potential benefits are expected to outweigh the risks in severe or life-threatening conditions (e.g. anthrax, Rocky Mountain spotted fever), particularly when there are no alternative therapies.

Clostridium difficile

C. difficile

C. difficile

C. difficile

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of , and surgical evaluation should be instituted as clinically indicated.

Intracranial hypertension (IH, pseudotumor cerebri) has been associated with the use of tetracyclines including MONODOX. Clinical manifestations of IH include headache, blurred vision, diplopia, and vision loss; papilledema can be found on fundoscopy. Women of childbearing age who are overweight or have a history of IH are at greater risk for developing tetracycline associated IH. Concomitant use of isotretinoin and MONODOX should be avoided because isotretinoin is also known to cause pseudotumor cerebri.

Although IH typically resolves after discontinuation of treatment, the possibility for permanent visual loss exists. If visual disturbance occurs during treatment, prompt ophthalmologic evaluation is warranted. Since intracranial pressure can remain elevated for weeks after drug cessation patients should be monitored until they stabilize.

All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in the fibula growth rate has been observed in prematures given oral tetracycline in doses of 25 mg/kg every six hours. This reaction was shown to be reversible when the drug was discontinued.

Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryo toxicity has been noted in animals treated early in pregnancy. If any tetracycline is used during pregnancy or if the patient becomes pregnant while taking these drugs, the patient should be apprised of the potential hazard to the fetus.

The antianabolic action of the tetracyclines may cause an increase in BUN. Studies to date indicate that this does not occur with the use of doxycycline in patients with impaired renal function.

Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.

Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.

Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.

Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.

Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.

The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.

Concurrent use of tetracycline may render oral contraceptives less effective.

As with other antibacterial preparations, use of this drug may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, MONODOX should be discontinued and appropriate therapy instituted.

Incision and drainage or other surgical procedures should be performed in conjunction with antibacterial therapy when indicated.

Prescribing MONODOX in the absence of proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Due to oral doxycycline’s virtually complete absorption, side effects to the lower bowel, particularly diarrhea, have been infrequent. The following adverse reactions have been observed in patients receiving tetracyclines.

Gastrointestinal:

Skin:

Renal Toxicity:

Hypersensitivity Reactions:

Blood:

Other:

When given over prolonged periods, tetracyclines have been reported to produce brown-black microscopic discoloration of the thyroid gland. No abnormalities of thyroid function are known to occur.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).